Government of Nova Scotia

Upon declaration of interchangeability in the Nova Scotia Formulary, the drug sponsor must provide written notification of any change made in the future to the Notice of Compliance, DIN, product name, ownership, manufacturer or distributor, cross-license and/ or distribution agreement, product formulation, site of manufacture, or any other significant product change which could be considered ... ................
................